Clinical trial

ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension

NCT06264622

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DIETARY_SUPPLEMENT · Unmapped registry intervention Low dose Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention High dose Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2024-02-26

PhaseNA

Conditions

Hypertensionunresolved

Interventions

Low doseDIETARY_SUPPLEMENT

High doseDIETARY_SUPPLEMENT

PlaceboDIETARY_SUPPLEMENT

Sponsors & collaborators

Universitat de Lleidalead sponsor

Pharmactive Biotech Products S.L.Ucollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06264622 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.